ImmunoCellular offering will support Phase II of autologous brain cancer vaccine
This article was originally published in Scrip
Executive Summary
ImmunoCellular Therapeutics, an emerging biotechnology company focused on developing novel immune-based therapies, is raising around $9.4 million through a public offering. The proceeds will be used to fund the ongoing Phase II trial of the company's promising autologous brain cancer vaccine, ICT-107.